[WCN23_Free Paper]

Neuromuscular

EFGARTIGIMOD DEMONSTRATES CONSISTENT IMPROVEMENTS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS OF SHORTER DISEASE DURATION 
Angela Genge (Canada)

LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CONCLUDING ANALYSES FROM THE ADAPT+ STUDY
Vera Bril (Canada)

THE ASTROCYTIC PHAGOCYTOSIS OF MYELIN DEBRIS AND REACTIVE CHARACTERISTICS IN VIVO AND IN VITRO
Hui-Jie Fan (China)

IS AGGREGATION OF SQSTM1 PROTEIN DEPENDENT ON ITS GENETIC AND TRANSCRIPTIONAL MODIFICATIONS IN IIM?
Bandana Jassal (India)

CHANGE IN CONCOMITANT THERAPIES FOR GENERALIZED MYASTHENIA GRAVIS IN PATIENTS RECEIVING ECULIZUMAB: A RETROSPECTIVE ANALYSIS OF REGISTRY DATA
Ema Rodrigues (United States of America)

DEVELOPMENT OF A GENE THERAPY TREATMENT FOR RYR1-RELATED DISEASES USING PRIME EDITING
Kelly Godbout (Canada)

EFGARTIGIMOD DEMONSTRATES CONSISTENT IMPROVEMENTS IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS REGARDLESS OF PRIOR TREATMENT FAILURES
Zaeem Siddiqi (Canada)